Raptopoulou-Gigi M, Ilonidis G, Orphanou-Koumerkeridou H, Preponis C, Sidiropoulos J, Lazaridis T, Goulis G
Second Medical Department, Aristotelian University, Thessaloniki, Greece.
J Investig Allergol Clin Immunol. 1993 Jul-Aug;3(4):192-7.
The effect of loratadine on the numbers of activated cells--cells expressing interleukin-2 receptors(IL-2R), HLA-DR antigens and proliferating cell nuclear antigen (PCNA)--in the nasal mucosa was studied in 48 patients with allergic rhinitis. Patients were treated with either loratadine (10 mg) or placebo for 1 month. At the end of treatment, a significant decrease in the symptom scores was noted in both groups of patients. However, the clinical score was significantly lower in the loratadine group compared to the placebo group. At the end of treatment, the numbers of IL-2R+, HLA-DR+ and PCNA+ cells were significantly decreased only in the group on loratadine. An almost significant correlation was also observed between the numbers of IL-2R+ cells and symptoms in the loratadine group. Our results show that loratadine exerts its beneficial effect possibly by inhibiting both the action of histamine and immune activation.
在48例变应性鼻炎患者中研究了氯雷他定对鼻黏膜中活化细胞数量的影响，这些活化细胞即表达白细胞介素-2受体（IL-2R）、HLA-DR抗原和增殖细胞核抗原（PCNA）的细胞。患者分别接受氯雷他定（10毫克）或安慰剂治疗1个月。治疗结束时，两组患者的症状评分均显著降低。然而，氯雷他定组的临床评分显著低于安慰剂组。治疗结束时，仅氯雷他定组的IL-2R+、HLA-DR+和PCNA+细胞数量显著减少。在氯雷他定组中，IL-2R+细胞数量与症状之间也观察到几乎显著的相关性。我们的结果表明，氯雷他定可能通过抑制组胺作用和免疫激活发挥其有益作用。
